Literature DB >> 24308720

The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.

Yi-Jing Chen1, Fei Hu, Chun-Yan Li, Jue-Min Fang, Li Chu, Xi Zhang, Qing Xu.   

Abstract

BACKGROUND: The UGT1A1*28 polymorphism is known as a biomarker of irinotecan-induced neutropenia in Caucasians. However, in Asians, the UGT1A1*28 mutation is much less frequent.
METHODS: A meta-analysis was performed to assess the association of the UGT1A1*6 and UGT1A1*28 with neutropenia in Asians.
RESULTS: In a combination test of the two variations, patients with severe neutropenia displayed a 155% higher mutational load than those that were not neutropenic (ORG = 2.55; 95% CI: 1.82-3.58).
CONCLUSIONS: In Asians, a combination test of UGT1A1*6 and UGT1A1*28 might be a potential biomarker of irinotecan-induced neutropenia, an observation that will need additional trials for confirmation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308720     DOI: 10.3109/1354750X.2013.867534

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  9 in total

1.  Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Authors:  Chalirmporn Atasilp; Mohitosh Biswas; Pimonpan Jinda; Nutthan Nuntharadthanaphong; Jiratha Rachanakul; Yaowaluck Hongkaew; Natchaya Vanwong; Surasak Saokaew; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

2.  Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project.

Authors:  Keiko Hikino; Takeshi Ozeki; Masaru Koido; Chikashi Terao; Yoichiro Kamatani; Yoshinori Murakami; Michiaki Kubo; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2019-10-04       Impact factor: 3.172

3.  An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.

Authors:  W Ichikawa; K Uehara; K Minamimura; C Tanaka; Y Takii; H Miyauchi; S Sadahiro; K Fujita; T Moriwaki; M Nakamura; T Takahashi; A Tsuji; K Shinozaki; S Morita; Y Ando; Y Okutani; M Sugihara; T Sugiyama; Y Ohashi; Y Sakata
Journal:  Br J Cancer       Date:  2015-04-16       Impact factor: 7.640

Review 4.  Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Authors:  Vid Mlakar; Patricia Huezo-Diaz Curtis; Chakradhara Rao Satyanarayana Uppugunduri; Maja Krajinovic; Marc Ansari
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

5.  Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.

Authors:  Xing-Han Liu; Jun Lu; Wei Duan; Zhi-Ming Dai; Meng Wang; Shuai Lin; Peng-Tao Yang; Tian Tian; Kang Liu; Yu-Yao Zhu; Yi Zheng; Qian-Wen Sheng; Zhi-Jun Dai
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

Review 6.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

Authors:  Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

7.  Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen.

Authors:  Xiaoqin Zhu; Jia Zhu; Feifei Sun; Zijun Zhen; Dalei Zhou; Suying Lu; Junting Huang; Yi Que; Lian Zhang; Ruiqing Cai; Juan Wang; Yizhuo Zhang
Journal:  Pharmgenomics Pers Med       Date:  2021-03-23

8.  Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor.

Authors:  Qian Li; Tao Sun; Hua Zhang; Wei Liu; Yu Xiao; Hongqi Sun; Wencheng Yin; Yanhong Yao; Yangchun Gu; Yan'e Liu; Fumei Yi; Qiqi Wang; Jinyu Yu; Baoshan Cao; Li Liang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

Review 9.  UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.

Authors:  Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.